# Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

> **NCT00094107** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Melanoma
- Skin Neoplasms

## Interventions

- **DRUG:** Axitinib [AG-013736]

## Key facts

- **NCT ID:** NCT00094107
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094107, "Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00094107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*